Skip to main content
. 2020 Mar 5;10(6):987–1003. doi: 10.1016/j.apsb.2020.02.015

Figure 1.

Figure 1

Effects of recombinant TIMP1 (rTIMP1) treatment on neurological outcomes after traumatic brain injury (TBI). (A) Recombinant TIMP1 protein expressed in eukaryotic cells (293T) was analyzed by SDS-PAGE and Western blots analysis. (B)–(E) TBI mice were injected with rTIMP1 (30, 90, and 270 μg/kg) or PBS daily through tail veins. Motor function were assessed at 24 and 72 h post-TBI (n = 13–15 per group). (B) Latency to fall from the accelerating Rota-rod. (C) The mean time taken to traverse the beam. (D) Hind limb motor scores in the beam walk test. (E) The number of hind limb foot-faults in the beam walk test. Data are presented as the mean ± SEM (ns, not significant; *P < 0.05; **P < 0.01).